Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNP002 in advanced solid tumors
NCT06466265Phase 1Recruiting
- Start
- May 2021
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DNP002 in solid tumor (advanced stage). Primary endpoints: Dose-limiting toxicity at 3 weeks, Incidence and severity of treatment emergent adverse events up to 2 years and 2 more. Started May 2021; status: recruiting.
02
Drugs
DNP002
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06466265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06466265.